Two Sigma Advisers
HOWL icon

Two Sigma Advisers’s Werewolf Therapeutics HOWL Stock Holding History

Two Sigma Advisers’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,300
Closed -$6.53K – 974
2025
Q4 		$6.53K Sell
10,300
-24,300
-70% -$29.5K ﹤0.01% 2327
2025
Q3 		$68.2K Sell
34,600
-22,000
-39% -$30.1K ﹤0.01% 2255
2025
Q2 		$61.7K Sell
56,600
-20,400
-26% -$21K ﹤0.01% 2243
2025
Q1 		$74.9K Sell
77,000
-62,100
-45% -$81.3K ﹤0.01% 2279
2024
Q4 		$206K Sell
139,100
-117,200
-46% -$239K ﹤0.01% 2118
2024
Q3 		$543K Buy
256,300
+17,000
+7% +$38.7K ﹤0.01% 1663
2024
Q2 		$584K Sell
239,300
-8,300
-3% -$39.9K ﹤0.01% 1811
2024
Q1 		$1.6M Buy
247,600
+70,300
+40% +$410K ﹤0.01% 1339
2023
Q4 		$684K Buy
+177,300
New +$453K ﹤0.01% 1794

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Two Sigma Advisers's HOWL Position: Q1 2026 in Review

Two Sigma Advisers sold out of Werewolf Therapeutics (HOWL) in Q1 2026, closing a stake of 10,300 shares — an estimated $6.53K sold.

Two Sigma Advisers first reported a position in HOWL in Q4 2023 and held it in 9 quarters. The position peaked at $1.6M in Q1 2024. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Two Sigma Advisers reported no remaining Werewolf Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Advisers sold 10,300 Werewolf Therapeutics shares in Q1 2026, an estimated $6.53K.
  • Two Sigma Advisers first reported a position in Werewolf Therapeutics in Q4 2023 and held it in 9 quarters.
  • Two Sigma Advisers's Werewolf Therapeutics position peaked at $1.6M in Q1 2024.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.